332 related articles for article (PubMed ID: 7572600)
1. Novel antiplatelet therapies for treatment of patients with ischemic heart disease: inhibitors of the platelet glycoprotein IIb/IIIa integrin receptor.
Frishman WH; Burns B; Atac B; Alturk N; Altajar B; Lerrick K
Am Heart J; 1995 Oct; 130(4):877-92. PubMed ID: 7572600
[TBL] [Abstract][Full Text] [Related]
2. The clinical role of platelet glycoprotein IIb/IIIa receptor inhibitors in ischemic heart disease.
Lefkovits J; Topol EJ
Cleve Clin J Med; 1996; 63(3):181-9. PubMed ID: 8665658
[TBL] [Abstract][Full Text] [Related]
3. Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective.
Dyke CM
Am Heart J; 1999 Oct; 138(4 Pt 2):307-16. PubMed ID: 10502236
[TBL] [Abstract][Full Text] [Related]
4. Current knowledge of the platelet glycoprotein IIb/IIIa receptor antagonists for the treatment of coronary artery disease.
Berkowitz SD
Haemostasis; 2000; 30 Suppl 3():27-43. PubMed ID: 11182626
[TBL] [Abstract][Full Text] [Related]
5. Platelet glycoprotein IIb/IIIa receptor inhibitors in ischemic heart disease.
Lefkovits J; Topol EJ
Curr Opin Cardiol; 1995 Jul; 10(4):420-6. PubMed ID: 7549085
[TBL] [Abstract][Full Text] [Related]
6. New antiplatelet agents: platelet GPIIb/IIIa antagonists.
Coller BS; Anderson K; Weisman HF
Thromb Haemost; 1995 Jul; 74(1):302-8. PubMed ID: 8578476
[TBL] [Abstract][Full Text] [Related]
7. Advancing the battle against acute ischemic syndromes: a focus on the GP IIb-IIIa inhibitors.
Dobesh PP; Latham KA
Pharmacotherapy; 1998; 18(4):663-85. PubMed ID: 9692642
[TBL] [Abstract][Full Text] [Related]
8. Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist.
Mousa SA; Bozarth JM; Forsythe MS; Jackson SM; Leamy A; Diemer MM; Kapil RP; Knabb RM; Mayo MC; Pierce SK
Circulation; 1994 Jan; 89(1):3-12. PubMed ID: 8281661
[TBL] [Abstract][Full Text] [Related]
9. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
[TBL] [Abstract][Full Text] [Related]
10. New antiplatelet agents.
White HD; French JK; Ellis CJ
Aust N Z J Med; 1998 Aug; 28(4):558-64. PubMed ID: 9777140
[TBL] [Abstract][Full Text] [Related]
11. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
Adgey AA
Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518
[TBL] [Abstract][Full Text] [Related]
12. Minimizing bleeding complications of percutaneous coronary intervention and glycoprotein IIb-IIIa antiplatelet therapy.
Juran NB
Am Heart J; 1999 Oct; 138(4 Pt 2):297-306. PubMed ID: 10502235
[TBL] [Abstract][Full Text] [Related]
13. Optimizing antiplatelet therapy in coronary interventions.
King SB
Clin Cardiol; 2000 Nov; 23 Suppl 6(Suppl 6):VI-8-13. PubMed ID: 11129685
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamic and clinical trials of glycoprotein IIb/IIIa inhibitors and potential relationship of results to dosing.
Hobbach HP; Schuster P
Z Kardiol; 2003 Mar; 92(3):213-8. PubMed ID: 12658467
[TBL] [Abstract][Full Text] [Related]
15. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors.
Peter K; Schwarz M; Ylänne J; Kohler B; Moser M; Nordt T; Salbach P; Kübler W; Bode C
Blood; 1998 Nov; 92(9):3240-9. PubMed ID: 9787160
[TBL] [Abstract][Full Text] [Related]
16. Platelet activation as a potential mechanism of GP IIb/IIIa inhibitor-induced thrombocytopenia.
Peter K; Straub A; Kohler B; Volkmann M; Schwarz M; Kübler W; Bode C
Am J Cardiol; 1999 Sep; 84(5):519-24. PubMed ID: 10482148
[TBL] [Abstract][Full Text] [Related]
17. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
Batchelor WB; Tolleson TR; Huang Y; Larsen RL; Mantell RM; Dillard P; Davidian M; Zhang D; Cantor WJ; Sketch MH; Ohman EM; Zidar JP; Gretler D; DiBattiste PM; Tcheng JE; Califf RM; Harrington RA
Circulation; 2002 Sep; 106(12):1470-6. PubMed ID: 12234950
[TBL] [Abstract][Full Text] [Related]
18. [Platelet glycoprotein IIB-IIIA receptor inhibitors in patients with ischemic heart disease].
Patti G; Fossati C; Manzoli A; D'Ambrosio A; Abbate A; Montesanti R; Di Sciascio G
Clin Ter; 2000; 151(4):301-6. PubMed ID: 11107681
[TBL] [Abstract][Full Text] [Related]
19. Labeling of the internal pool of GP IIb-IIIa in platelets by c7E3 Fab fragments (abciximab): flow and endocytic mechanisms contribute to the transport.
Nurden P; Poujol C; Durrieu-Jais C; Winckler J; Combrié R; Macchi L; Bihour C; Wagner C; Jordan R; Nurden AT
Blood; 1999 Mar; 93(5):1622-33. PubMed ID: 10029591
[TBL] [Abstract][Full Text] [Related]
20. Antiplatelet therapy with glycoprotein IIb/IIIa receptor inhibitors and other novel agents.
Schafer AI
Tex Heart Inst J; 1997; 24(2):90-6. PubMed ID: 9205981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]